Baltimore Business Journal: Biopharma Gliknik Inc. raises $11.5M to fuel drug development, trials
Thursday, June 24, 2021
A Baltimore biopharmaceutical has raised $11.5 million in new capital to fund efforts to create therapies for people living with cancer and autoimmune disorders.
Gliknik Inc.'s Series C fundraise was led by First In Ventures (FIV), with SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings participating. The company has secured $81 million in funding to date, including about $34 million in venture capital and $47 million in other non-dilutive funding. And it announced this latest round will help to advance several of its drug candidates through various clinical phases.
CEO David Block said in addition to the fresh capital, this round has brought new investors with strong connections in the biotech industry, and shows that "people still believe in what we’re doing."
Read the full story from the Baltimore Business Journal.